Skip to main content

British National Formulary October 2024 Update

This update contains 11 significant changes, 2 dose changes and 3 new monographs.

Significant Changes:

  • Borderline substances: enteral (tube) feeds have been re-organised in a new section called Enteral nutrition.
  • Cholera vaccines: updated guidance for immunisation.
  • Epimax® ointment and Epimax® paraffin-free ointment: reports of ocular surface toxicity and ocular chemical injury [MHRA/CHM advice] (advice in emollient creams and ointments, paraffin-containing and emollient creams and ointments, hydrogenated castor oil-containing).
  • Human papillomavirus vaccine: updated guidance for immunisation.
  • Immunisation schedule: updated guidance.
  • Poisoning, emergency treatment: updated guidance for paracetamol overdose.
  • Posaconazole: important safety information added to highlight that tablets and oral suspension are not directly interchangeable.
  • Sacubitril with valsartan: update to dose expression.
  • Sodium valproate: new precautionary advice for male patients [MHRA/CHM advice].
  • Status epilepticus: updated guidance for management.
  • Valproic acid: new precautionary advice for male patients [MHRA/CHM advice].

Dose Changes:

  • Human papillomavirus vaccine [update to dosing].
  • Levonorgestrel [update to indications and dose for intra-uterine devices].

New Monographs:

  • Eladynos® [abaloparatide].
  • Emollient creams and ointments, hydrogenated castor oil-containing.
  • Pylera® [bismuth potassium with metronidazole and tetracycline hydrochloride].